AI-generated analysis. Always verify with the original filing.
Cognition Therapeutics, Inc. reported financial results for the year ended December 31, 2025, with a net loss of $23.5 million or $(0.32) per share, improved from $34.0 million or $(0.86) per share in 2024, and cash of $37.0 million sufficient through Q2 2027. The company provided clinical updates on zervimesine, including published Phase 2 SHIMMER results in DLB psychosis, planned FDA meeting mid-2026, and completed enrollment in Phase 2 START trial in early Alzheimer's with results in 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
(including Exhibit 99.2) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be “filed” for the purposes of Sectio
Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Press Release, dated March 26, 20
| Metric | Value | Basis |
|---|---|---|
| Research and development expenses | $37.20 | GAAP |
| General and administrative expenses | $10.60 | GAAP |
| Total operating expenses | $47.80 | GAAP |
| Loss from operations | $-47.80 | GAAP |
| Net loss | $-23.50 | GAAP |
| Net loss per share basic | $-0.32 | GAAP |
| Net loss per share diluted | $-0.32 | GAAP |